Table 2. Effect of treatment regimen on outcome, by initial resistance profile, in 7291 patients.

	Programmatically adverse outcome†					Bacteriologically adverse outcome‡
	Total	n	%	OR	[95%CI]	Total	n	%	OR	[95%CI]
Initially susceptible to RMP and INH
6-month RMP-throughout regimen §	1629	176	10.8	1		1524	71	4.7	1
2(3)EHRZ/6HT	1349	187	13.9	1.3*	[1.1,1.7]	1210	48	4.0	0.8	[0.6,1.2]
2SEHRZ/1(2)EHRZ/5EHR	2759	489	17.7	1.8***	[1.5,2.1]	2374	104	4.4	0.9	[0.7,1.3]
Initially resistant to RMP
6-month RMP-throughout regimen §	30	18	60.0	1		26	14	53.8	1
2(3)EHRZ/6HT	20	12	60.0	1	[0.3,3.2]	17	9	52.9	1	[0.3,3.3]
2SEHRZ/1(2)EHRZ/5EHRE	571	402	70.4	1.6	[0.7,3.4]	443	274	61.9	1.4	[0.6,3.1]
RMP susceptible, INH resistant
6-month RMP-throughout regimen §	108	7	6.5	1		105	4	3.8	1
2(3)EHRZ/6HT	102	36	35.3	7.9***	[3.3,18.7]	91	25	27.5	9.6***	[3.2,28.7]
2SEHRZ/1(2)EHRZ/5EHR	723	142	19.6	3.5**	[1.6,7.8]	629	48	7.6	2.1	[0.7,5.9]

INH or H: isoniazid; RMP or R: rifampicin; E: ethambutol; S: streptomycin; T: thioacetazone; Z: pyrazinamide; OR: odds ratio

Preceding numbers in regimens are months of treatment; subscript numbers indicate intermittent number of doses of preceding drug per week

Level of significance:

** p<0.01;

*** p<0.001

^† programmatically adverse: failure, relapse, death or LTFU

^‡ bacteriologically adverse: failure or relapse

^§ either 2(3)EHRZ/4H₃R₃, 2(3)EHRZ/4HR, or 2EHR^hZ/4HR^h